Oxybutynin for Nocturnal Enuresis
Oxybutynin can be used for nocturnal enuresis, but only as second-line therapy in children who have failed standard first-line treatments (enuresis alarm and/or desmopressin), and specifically when there is evidence of detrusor overactivity or when combined with desmopressin. 1
Treatment Algorithm
First-Line Therapy (Must Try First)
- Enuresis alarm or desmopressin are the only evidence-based first-line treatments 1
- Behavioral interventions: regular voiding habits, fluid restriction in evening, treating constipation
When to Consider Oxybutynin (Second-Line Only)
Prerequisites before prescribing oxybutynin: 1
- Standard treatment has failed (alarm and/or desmopressin)
- Complete frequency-volume chart to document voiding patterns
- Perform uroflowmetry with post-void residual ultrasound to exclude:
- Post-void residual urine
- Dysfunctional voiding
- Low voiding frequency
- Exclude or treat constipation first
- Try nonpharmacological methods to decrease detrusor overactivity (regular voiding habits)
Dosing and Efficacy
- Dose: 5 mg oxybutynin at bedtime (may need to double) 1
- Expected response: Effective in approximately 40% of therapy-resistant children 1
- Time to effect: Should appear within maximum of 2 months, sometimes earlier 1
- Combination therapy: Often requires desmopressin at standard dose for optimal results 1, 2
Evidence Quality and Nuances
The International Children's Continence Society guideline 1 explicitly states that anticholinergics like oxybutynin "cannot as yet be considered evidence-based first line therapy for nocturnal enuresis." However, they suppress detrusor overactivity which may be present even in monosymptomatic nocturnal enuresis. Recent randomized placebo-controlled studies have corroborated earlier open studies showing benefit in therapy-resistant cases.
Research evidence supports combination therapy: A 2005 randomized controlled trial 2 found that desmopressin plus oxybutynin produced significantly faster and more cost-effective results than either desmopressin or imipramine alone, regardless of whether children had monosymptomatic or polysymptomatic enuresis. A 2021 study 3 showed 92.2% complete response at 6 months with combination therapy versus 79.5% with desmopressin alone.
Important contradiction: One 2016 study 4 found desmopressin superior to oxybutynin monotherapy with fewer side effects, reinforcing that oxybutynin should not be used as monotherapy for simple nocturnal enuresis.
Critical Safety Concerns
Most bothersome side effect: Constipation, which may herald decreasing anti-enuretic effect 1
Greatest danger: Post-void residual urine causing UTIs 1
- Child must maintain sound voiding habits
- Family must watch for dysuria or unexplained fever
Other side effects:
- Mood changes (less common with tolterodine or propiverine alternatives) 1
- Xerostomia and blurred vision 4
- Facial flushing 5
FDA labeling: 6 Oxybutynin is indicated for bladder instability with voiding symptoms (urgency, frequency, urge incontinence). Safety and efficacy demonstrated for pediatric patients ≥5 years of age, particularly those with detrusor overactivity associated with neurological conditions.
Common Pitfalls to Avoid
- Do not use oxybutynin as first-line therapy - this violates guideline recommendations 1
- Do not prescribe without proper urological workup - frequency-volume chart and uroflowmetry with post-void residual are mandatory 1
- Do not ignore constipation - must be treated before starting anticholinergics 1
- Do not use as monotherapy - combination with desmopressin is usually needed for optimal results 1, 2
- Do not forget to monitor - watch for urinary retention, UTI symptoms, and decreasing efficacy suggesting constipation 1